Cargando…

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China

Objective: The primary purpose of this study was to estimate the cost-effectiveness of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Methods: We updated and utilized a previously validated Markov microsimulation model to obtai...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Ruxu, Liu, Jinyu, Ke, Lei, Wan, Min, Zhang, Yu, Yu, Guangyi, Mori, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971554/
https://www.ncbi.nlm.nih.gov/pubmed/35370751
http://dx.doi.org/10.3389/fphar.2022.816248
_version_ 1784679659653300224
author You, Ruxu
Liu, Jinyu
Ke, Lei
Wan, Min
Zhang, Yu
Yu, Guangyi
Mori, Takahiro
author_facet You, Ruxu
Liu, Jinyu
Ke, Lei
Wan, Min
Zhang, Yu
Yu, Guangyi
Mori, Takahiro
author_sort You, Ruxu
collection PubMed
description Objective: The primary purpose of this study was to estimate the cost-effectiveness of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Methods: We updated and utilized a previously validated Markov microsimulation model to obtain the cost-effectiveness of two strategies for treating postmenopausal osteoporotic women. We compared the incremental cost-effectiveness ratios (ICERs) (US dollars [$] per quality-adjusted life year [QALY]) of sequential denosumab/zoledronic acid (i.e., biannual subcutaneous denosumab for 3 years followed by annual intravenous zoledronic acid for 3 years) with zoledronic acid monotherapy for 3 years in Chinese women with postmenopausal osteoporosis at ages 65, 70, 75, and 80 from the health care payer perspective. Our study’s willingness-to-pay (WTP) threshold was set to three times the value of China’s per capita GDP in 2020 ($31,512). Results: The ICERs of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy were $59,389/QALY, $23,821/QALY, $22,710/QALY, and $14,027/QALY at age 65, 70, 75, and 80 years, respectively. One-way sensitivity analyses showed that the most impactful parameter was the persistence rate of the medications. If the persistence rate of denosumab or zoledronic acid was increased by 10%, sequential denosumab/zoledronic acid would be cost-effective at age 65. In probabilistic sensitivity analyses, the probabilities of sequential denosumab/zoledronic being cost-effective compared to zoledronic acid monotherapy were approximately 29.3%, 68.7%, 86.1%, and 99.4% for ages 65, 70, 75, and 80 years, respectively, at the WTP threshold of $31,512/QALY. Conclusion: Among Chinese postmenopausal osteoporosis women over 70 years old, sequential denosumab/zoledronic acid was cost-effective compared with zoledronic acid monotherapy at the pre-determined WTP threshold.
format Online
Article
Text
id pubmed-8971554
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89715542022-04-02 Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China You, Ruxu Liu, Jinyu Ke, Lei Wan, Min Zhang, Yu Yu, Guangyi Mori, Takahiro Front Pharmacol Pharmacology Objective: The primary purpose of this study was to estimate the cost-effectiveness of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Methods: We updated and utilized a previously validated Markov microsimulation model to obtain the cost-effectiveness of two strategies for treating postmenopausal osteoporotic women. We compared the incremental cost-effectiveness ratios (ICERs) (US dollars [$] per quality-adjusted life year [QALY]) of sequential denosumab/zoledronic acid (i.e., biannual subcutaneous denosumab for 3 years followed by annual intravenous zoledronic acid for 3 years) with zoledronic acid monotherapy for 3 years in Chinese women with postmenopausal osteoporosis at ages 65, 70, 75, and 80 from the health care payer perspective. Our study’s willingness-to-pay (WTP) threshold was set to three times the value of China’s per capita GDP in 2020 ($31,512). Results: The ICERs of sequential denosumab/zoledronic acid versus zoledronic acid monotherapy were $59,389/QALY, $23,821/QALY, $22,710/QALY, and $14,027/QALY at age 65, 70, 75, and 80 years, respectively. One-way sensitivity analyses showed that the most impactful parameter was the persistence rate of the medications. If the persistence rate of denosumab or zoledronic acid was increased by 10%, sequential denosumab/zoledronic acid would be cost-effective at age 65. In probabilistic sensitivity analyses, the probabilities of sequential denosumab/zoledronic being cost-effective compared to zoledronic acid monotherapy were approximately 29.3%, 68.7%, 86.1%, and 99.4% for ages 65, 70, 75, and 80 years, respectively, at the WTP threshold of $31,512/QALY. Conclusion: Among Chinese postmenopausal osteoporosis women over 70 years old, sequential denosumab/zoledronic acid was cost-effective compared with zoledronic acid monotherapy at the pre-determined WTP threshold. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971554/ /pubmed/35370751 http://dx.doi.org/10.3389/fphar.2022.816248 Text en Copyright © 2022 You, Liu, Ke, Wan, Zhang, Yu and Mori. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
You, Ruxu
Liu, Jinyu
Ke, Lei
Wan, Min
Zhang, Yu
Yu, Guangyi
Mori, Takahiro
Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title_full Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title_fullStr Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title_full_unstemmed Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title_short Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
title_sort cost-effectiveness of sequential denosumab/zoledronic acid compared with zoledronic acid monotherapy for postmenopausal osteoporotic women in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971554/
https://www.ncbi.nlm.nih.gov/pubmed/35370751
http://dx.doi.org/10.3389/fphar.2022.816248
work_keys_str_mv AT youruxu costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT liujinyu costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT kelei costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT wanmin costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT zhangyu costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT yuguangyi costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina
AT moritakahiro costeffectivenessofsequentialdenosumabzoledronicacidcomparedwithzoledronicacidmonotherapyforpostmenopausalosteoporoticwomeninchina